Celecoxib Combined with Thalidomide in the Treatment of Refractory Neoplastic Fever in Advanced Cholangiocarcinoma: A Case Report

A B S T R A C T

Neoplastic fever, a common symptom of tumors, can be mainly controlled by nonsteroidal anti-inflammatories (NSAIDs) and corticosteroids. However, there is no standard treatment guideline for refractory neoplastic fever, which cannot be controlled by the medicines mentioned above. This report presents a case of advanced cholangiocarcinoma with persistent fever lasting 3 weeks. After ineffective treatment with various antibiotics, ibuprofen, and corticosteroids, the body temperature returned to normal after a 48-hour treatment with celecoxib + thalidomide. Finally, the overall survival (OS) of the patient reached 8 months with radiotherapy and chemotherapy.

Keywords

Celecoxib, thalidomide, neoplastic fever, cholangiocarcinoma



Get access to the full version of this article.

Article Info

Article Type
Case Report
Publication history
Received: Wed 02, Dec 2020
Accepted: Fri 18, Dec 2020
Published: Wed 23, Dec 2020
Copyright
© 2023 Kaijian Lei. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.JSO.2020.06.06

Author Info

Qiu-yuan Liang Kaijian Lei Shan-Bing Wang Yue Ren Yan Xu

Corresponding Author
Kaijian Lei
Department of Oncology, The Second People’s Hospital of Yibin, Yibin, Sichuan, China

Figures & Tables



Get access to the full version of this article.

References

  1. Browder AA, Huff JW, Petersdorf RG (1961) The significance of fever in neoplastic disease. Ann Intern Med 55: 932-942. [Crossref]
  2. Toussaint E, Bahel Ball E, Vekemans M, Georgala A, Al Hakak L et al. (2006) Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer 14: 763-769. [Crossref]
  3. Zell JA, Chang JC (2005) Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer 13: 870-877. [Crossref]
  4. Johnson M (1996) Neoplastic Fever. Palliat Med 10: 217-224. [Crossref]
  5. Chang JC (1988) Antipyretic effect of naproxen and corticosteroidss on neoplastic fever. J Pain Symptom Manage 3: 141-144. [Crossref]
  6. Tsavaris N, Zinelis A, Karabelis A, Beldecos D, Bacojanis C et al. (1990) A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med 228: 451-455. [Crossref]
  7. Rolston KVI (2005) Neoplastic fever: all who shiver are not infected. Support Care Cancer 13: 863-864. [Crossref]
  8. Farley DR, Weaver AL, Nagorney DM (1995) “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 70: 425-429. [Crossref]
  9. Gong ZJ, Cheng JW, Gao PT, Huang A, Sun YF et al. (2019) Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. Oncologist 24: 997-1007. [Crossref]
  10. Rizvi S, Gores GJ (2013) Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. Gastroenterology 145: 1215-1229. [Crossref]
  11. Wójcik M, Ramadori P, Blaschke M, Sultan S, Khan S et al. (2012) Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma. Histochem Cell Biol 137: 217-233. [Crossref]
  12. Furey SA, Waksman JA, Dash BH (1992) Nonprescription ibuprofen: side effect profile. Pharmacotherapy 12: 403-407. [Crossref]
  13. Lipsky PE, Isakson PC (1997) Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol Suppl 49: 9-14. [Crossref]
  14. Chaulet C, Croix C, Alagille D, Normand S, Delwail A et al. (2011) Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors. Bioorg Med Chem Lett 21: 1019-1022. [Crossref]
  15. Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH et al. (2003) Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 9: 1302-1306. [Crossref]
  16. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T et al. (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425. [Crossref]
  17. Liu KH, Liao LM, Ro LS, Wu YL, Yeh TS (2008) Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats. Surgery 143: 375-383. [Crossref]
  18. Hada M, Horiuchi T, Shinji H (2006) A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine. Gan to Kagaku Ryoho 33: 259-261. [Crossref]
  19. Wang XS, Woodruff JF (2015) Cancer-related and treatment-related fatigue. Gynecol Oncol 136: 446-452. [Crossref]
  20. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703. [Crossref]